1998
DOI: 10.1515/revneuro.1998.9.1.17
|View full text |Cite
|
Sign up to set email alerts
|

A Novel Prolyl Endopeptidase Inhibitor, JTP-4819 - Its Behavioral and Neurochemical Properties for the Treatment of Alzheimer's Disease

Abstract: Formation of beta-amyloid and neurofibrillary tangles in the brain due to genetic or other factors is the most frequent cause of Alzheimer's disease. In addition, marked reduction of certain brain neuropeptide levels is a consistent finding in patients with Alzheimer's disease, together with the deterioration of cholinergic neurons. Currently, there is great demand for the development of new drugs to improve memory deficits or to delay the neurodegenerative process in conditions such as Alzheimer's disease. In… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
19
0

Year Published

2002
2002
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 28 publications
(20 citation statements)
references
References 72 publications
1
19
0
Order By: Relevance
“…It has been shown previously that selective PEP inhibitors suppress in vitro ␤-amyloid protein formation (Shinoda et al, 1997) and prevent in vivo amyloid deposition in the hippocampus of senescence-accelerated mice (Kato et al, 1997). Thus, the present data showing that the cerebral cortex and hippocampus are enriched with PEP mRNA support the view that PEP inhibitors may represent a new therapeutic approach for the treatment of Alzheimer's disease (Kato et al, 1997;Toide et al, 1998).…”
Section: Functional Implicationssupporting
confidence: 82%
“…It has been shown previously that selective PEP inhibitors suppress in vitro ␤-amyloid protein formation (Shinoda et al, 1997) and prevent in vivo amyloid deposition in the hippocampus of senescence-accelerated mice (Kato et al, 1997). Thus, the present data showing that the cerebral cortex and hippocampus are enriched with PEP mRNA support the view that PEP inhibitors may represent a new therapeutic approach for the treatment of Alzheimer's disease (Kato et al, 1997;Toide et al, 1998).…”
Section: Functional Implicationssupporting
confidence: 82%
“…40) Previous studies on inhibitors of prolyl endopeptidase focused primarily on proline peptides and mimetics. 41) To the best of our knowledge, the inhibitory activities of procyanidins on prolyl endopeptidase have not been reported.…”
Section: Protease Inhibitory Activitiesmentioning
confidence: 99%
“…Speculations about these physiological roles of POP have gained some support from neuroprotective and cognition-enhancing effects of POP inhibitors [20,21,22]. In some drug- or lesion-induced amnesia models and in aged rodents, POP inhibitors have been able to reverse memory loss, although the results are not convincing [14].…”
Section: Introductionmentioning
confidence: 99%